-0.90% sank 6.7% toward an 8-month low in morning trading Thursday, a district court in West Virginia invalidated a patent on Biogen's multiple sclerosis treatment Tecfidera, which is a ruling in favor of Mylan Inc.Biogen said Thursday it plans to appeal the decision on the patent, covering the Tecfidera daily dosing regimen of 480 milligrams per day.